Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Beverly M.K. Biller, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Beverly Biller and Anne Klibanski.
Beverly Biller
Connection Strength
4.262
Anne Klibanski
  1. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency. J Clin Endocrinol Metab. 2000 Mar; 85(3):970-6.
    View in: PubMed
    Score: 0.215
  2. A decade of the Massachusetts General Hospital Neuroendocrine Clinical Center. J Clin Endocrinol Metab. 1997 Jun; 82(6):1668-74.
    View in: PubMed
    Score: 0.178
  3. Effectiveness of first-line pegvisomant monotherapy in acromegaly: an ACROSTUDY analysis. Eur J Endocrinol. 2017 Feb; 176(2):213-220.
    View in: PubMed
    Score: 0.171
  4. Dopamine Agonists Can Reduce Cystic Prolactinomas. J Clin Endocrinol Metab. 2016 10; 101(10):3709-3715.
    View in: PubMed
    Score: 0.168
  5. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab. 1996 Jun; 81(6):2338-43.
    View in: PubMed
    Score: 0.166
  6. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis. J Clin Endocrinol Metab. 2014 Jun; 99(6):2018-29.
    View in: PubMed
    Score: 0.143
  7. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014 Apr; 17(2):150-6.
    View in: PubMed
    Score: 0.143
  8. Pathologic and clinical features of pituitary adenomas showing TSH immunoreactivity. Pituitary. 2013 Sep; 16(3):287-93.
    View in: PubMed
    Score: 0.137
  9. Clonal origins of adrenocorticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab. 1992 Nov; 75(5):1303-9.
    View in: PubMed
    Score: 0.130
  10. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab. 1992 Sep; 75(3):692-7.
    View in: PubMed
    Score: 0.128
  11. Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol. 1991 Dec; 78(6):996-1001.
    View in: PubMed
    Score: 0.122
  12. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab. 2010 Mar; 95(3):1025-33.
    View in: PubMed
    Score: 0.107
  13. Abnormal cortisol secretion and responses to corticotropin-releasing hormone in women with hypothalamic amenorrhea. J Clin Endocrinol Metab. 1990 Feb; 70(2):311-7.
    View in: PubMed
    Score: 0.107
  14. Delayed remission after transsphenoidal surgery in patients with Cushing's disease. J Clin Endocrinol Metab. 2010 Feb; 95(2):601-10.
    View in: PubMed
    Score: 0.107
  15. Growth hormone deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab. 2010 Feb; 95(2):567-77.
    View in: PubMed
    Score: 0.107
  16. Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest. 2009 Dec; 32(11):924-33.
    View in: PubMed
    Score: 0.106
  17. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome. J Clin Endocrinol Metab. 2009 Dec; 94(12):4851-9.
    View in: PubMed
    Score: 0.105
  18. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010 Jan; 72(1):53-8.
    View in: PubMed
    Score: 0.101
  19. Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa. J Clin Endocrinol Metab. 1989 Mar; 68(3):548-54.
    View in: PubMed
    Score: 0.100
  20. Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008 Jul; 93(7):2454-62.
    View in: PubMed
    Score: 0.095
  21. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008 Jun; 93(6):2063-71.
    View in: PubMed
    Score: 0.094
  22. Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin Endocrinol Metab. 2007 Jul; 92(7):2474-9.
    View in: PubMed
    Score: 0.088
  23. Effects of testosterone replacement in androgen-deficient women with hypopituitarism: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2006 May; 91(5):1683-90.
    View in: PubMed
    Score: 0.081
  24. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab. 2005 Feb; 90(2):768-74.
    View in: PubMed
    Score: 0.075
  25. Diagnostic errors after inferior petrosal sinus sampling. J Clin Endocrinol Metab. 2004 Aug; 89(8):3752-63.
    View in: PubMed
    Score: 0.073
  26. The role of the clinical laboratory in the diagnosis of Cushing syndrome. Am J Clin Pathol. 2003 Dec; 120 Suppl:S38-45.
    View in: PubMed
    Score: 0.070
  27. Androgens and bone density in women with hypopituitarism. J Clin Endocrinol Metab. 2002 Jun; 87(6):2770-6.
    View in: PubMed
    Score: 0.063
  28. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J Clin Endocrinol Metab. 2001 Apr; 86(4):1518-24.
    View in: PubMed
    Score: 0.058
  29. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000 Jul 18; 133(2):111-22.
    View in: PubMed
    Score: 0.055
  30. Accuracy of Laboratory Tests for the Diagnosis of Cushing Syndrome. J Clin Endocrinol Metab. 2020 06 01; 105(6).
    View in: PubMed
    Score: 0.055
  31. All-cause mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis. Eur J Endocrinol. 2020 Mar; 182(3):285-292.
    View in: PubMed
    Score: 0.054
  32. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficiency. J Clin Endocrinol Metab. 1998 Sep; 83(9):3184-9.
    View in: PubMed
    Score: 0.049
  33. Characterization of cyclic Cushing's disease using late night salivary cortisol testing. Clin Endocrinol (Oxf). 2018 09; 89(3):336-345.
    View in: PubMed
    Score: 0.048
  34. Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly. Pituitary. 2017 Dec; 20(6):668-675.
    View in: PubMed
    Score: 0.046
  35. Bone microarchitecture and estimated bone strength in men with active acromegaly. Eur J Endocrinol. 2017 Nov; 177(5):409-420.
    View in: PubMed
    Score: 0.045
  36. Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting. J Clin Endocrinol Metab. 1997 May; 82(5):1332-7.
    View in: PubMed
    Score: 0.044
  37. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996 Dec 01; 125(11):883-90.
    View in: PubMed
    Score: 0.043
  38. Assessment of growth hormone (GH) secretion in men with adult-onset GH deficiency compared with that in normal men--a clinical research center study. J Clin Endocrinol Metab. 1996 Jan; 81(1):84-92.
    View in: PubMed
    Score: 0.040
  39. Accuracy of Late-Night Salivary Cortisol in Evaluating Postoperative Remission and Recurrence in Cushing's Disease. J Clin Endocrinol Metab. 2015 Oct; 100(10):3770-7.
    View in: PubMed
    Score: 0.039
  40. The effects of estrogen administration on trabecular bone loss in young women with anorexia nervosa. J Clin Endocrinol Metab. 1995 Mar; 80(3):898-904.
    View in: PubMed
    Score: 0.038
  41. Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly. Clin Endocrinol (Oxf). 2012 Sep; 77(3):430-8.
    View in: PubMed
    Score: 0.032
  42. Transsphenoidal surgery for cushing disease after nondiagnostic inferior petrosal sinus sampling. Neurosurgery. 2012 Jul; 71(1):14-22.
    View in: PubMed
    Score: 0.032
  43. Effect of growth hormone replacement therapy on the quality of life in women with growth hormone deficiency who have a history of acromegaly versus other disorders. Endocr Pract. 2012 Mar-Apr; 18(2):209-18.
    View in: PubMed
    Score: 0.031
  44. Osteopenia in men with a history of delayed puberty. N Engl J Med. 1992 Feb 27; 326(9):600-4.
    View in: PubMed
    Score: 0.031
  45. Adipokines and cardiovascular risk in Cushing's syndrome. Neuroendocrinology. 2012; 95(3):187-206.
    View in: PubMed
    Score: 0.030
  46. Clinical features of nonpituitary sellar lesions in a large surgical series. Clin Endocrinol (Oxf). 2010 Dec; 73(6):798-807.
    View in: PubMed
    Score: 0.028
  47. Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest. 1990 Jul; 86(1):336-40.
    View in: PubMed
    Score: 0.028
  48. Age and bone mass in premenopausal women. J Bone Miner Res. 1989 Aug; 4(4):533-8.
    View in: PubMed
    Score: 0.026
  49. Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab. 2009 Jul; 94(7):2471-7.
    View in: PubMed
    Score: 0.025
  50. Gonadotropin and alpha-subunit responses to chronic gonadotropin-releasing hormone analog administration in patients with glycoprotein hormone-secreting pituitary tumors. J Clin Endocrinol Metab. 1989 Jan; 68(1):81-6.
    View in: PubMed
    Score: 0.025
  51. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab. 1988 Jul; 67(1):124-30.
    View in: PubMed
    Score: 0.024
  52. Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clin Neurosurg. 2008; 55:141-4.
    View in: PubMed
    Score: 0.023
  53. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab. 2008 Feb; 93(2):393-9.
    View in: PubMed
    Score: 0.023
  54. Proton stereotactic radiosurgery in management of persistent acromegaly. Endocr Pract. 2007 Nov-Dec; 13(7):726-34.
    View in: PubMed
    Score: 0.023
  55. Diagnostic dilemmas in the management of hypothalamic-pituitary-adrenal disorders. Ann N Y Acad Sci. 1987; 512:338-50.
    View in: PubMed
    Score: 0.022
  56. Growth hormone (GH) replacement therapy in adult-onset gh deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004 May; 89(5):2048-56.
    View in: PubMed
    Score: 0.018
  57. Long-term mortality after transsphenoidal surgery for Cushing disease. Ann Intern Med. 1999 May 18; 130(10):821-4.
    View in: PubMed
    Score: 0.013
  58. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab. 1998 Oct; 83(10):3419-26.
    View in: PubMed
    Score: 0.012
  59. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J Neurosurg. 1993 May; 78(5):753-61.
    View in: PubMed
    Score: 0.008
  60. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann Intern Med. 1990 May 01; 112(9):668-73.
    View in: PubMed
    Score: 0.007
  61. Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology. 1989 Feb; 170(2):515-8.
    View in: PubMed
    Score: 0.006
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.